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How structure informs and transforms chemogenetics
Bryan L RothChemogenetic technologies such as Designer Receptors
Exclusively Activated by Designer Drugs (DREADDs) are widely
used to remotely control neuronal and non-neuronal signaling.
DREADDs exist for most of the canonical G protein-coupled
receptor signaling pathways, and provide a synthetic biology
platform useful for elucidating the role of neuronal signaling for
brain function. Here, a focused review is provided that shows
how recent insights obtained from GPCR structural studies
inform our understanding of these chemogenetic tools from a
structural perspective.
Address
Department of Pharmacology and Division of Medicinal Chemistry and
Chemical Biology, University of North Carolina, Chapel Hill School of
Medicine, Chapel Hill, NC 27514, United States
Corresponding author: Roth, Bryan L (bryan_roth@med.unc.edu)
Current Opinion in Structural Biology 2019, 57:9–16
This review comes from a themed issue on Engineering and design: 
synthetic signaling
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Introduction
G protein-coupled receptors (GPCRs) — with more than
800 members — represent the largest family of mem-
brane proteins in the human genome [1]. GPCRs also
represent the single largest family of therapeutic drug
targets in the druggable genome [2], with 20–30% of
approved drugs having GPCRs as their major molecular
target [3,4]. GPCRs are expressed in essentially every
major organ in the body, with approximately 80% being
expressed in the brain [5]; many GPCRs have their
highest level of expression in nervous tissue [5]. GPCRs
transduce their signals via binding to and activating
hetereotrimeric G proteins; G proteins couple to various
downstream effectors to modulate second messengers
including cAMP, inositol trisphosphate (IP3), calcium
(Ca2+) and others [3]. GPCRs also can signal via arrestin
proteins [6] which bind to activated GPCRs following
phosphorylation by G protein receptor kinases (GRKs)
[7]. Arrestins also arrest G-protein signaling and interact
with clathrin to promote endocytosis [8].Within neurons, GPCRs, via G protein activation, regu-
late neuronal excitability [9], vesicle release [10], ion
channel activity [11,12], and a variety of intracellular
second messengers [see Ref. [13] for review]. How these
alterations in neuronal signaling and firing ultimately
result in various brain processes such as perception,
cognition, emotion, motivation, and so on is yet unclear.
Some years ago, Francis Crick proposed that in order to
ultimately understand the neuronal basis of these brain
activities [14,15] we would need:
“ . . . to identify the many different types of neu-
rons in the cerebral cortex and other parts of the
brain. One of the next requirements . . . is to be
able to turn the firing of one or more types of neuron
on and off in the alert animal . . . One way-out
suggestion is to engineer these neurons so that
when one of them fires it would emit a flash of
light of a particular wavelength . . . ” [15]
The past decade has seen remarkable progress on this
front and essentially all of the items in Crick’s ‘wish list’
are in place. First, RNA-seq based technologies have
begun cataloging the many different types of neurons
[16] and large numbers of engineered mouse lines are
available to ultimately provide genetic access to individ-
ual types of neurons [17,18]. Second, optogenetic
[19,20] and chemogenetic [21,22] technologies have
provided tools ‘to turn the firing of one or more types of
neuron on and off in the alert animal’. Finally, genetically
encoded calcium [23] and voltage [24] sensors are avail-
able to image neurons that ‘emit a flash of light of a
particular wavelength’ [25] and be visualized with fiber
optics [26] and miniature microscopes [27].
It still remains unclear; however, how GPCR signaling is
ultimately harnessed by neurons to modulate various brain
functions. Given the vast number of neuronal phenomena
that can be modulated, engineering synthetic ligands and
GPCRs that can be used to remotely control neuronal could
provide a technology useful for elucidating the role of
GPCRs in brain function. For decades, it has been appre-
ciated that if one could engineer GPCRs so that they could
be activated by an inert drug but were insensitive to their
endogenous ligand, they could be used to illuminate the
role of GPCR signaling in these processes [28–30]. The
notion was that once such ‘designer receptor/ligand pairs’
were created, they could be expressed in defined cell types
via transgenic or viral methods. Behavioral and physiologi-
cal monitoring before and after activation by the designed
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DREADD-based chemogenetic tools modulate cellular function.
Shown is a hypothetical pancreatic beta cell wherein a Gq-coupled DREADD can be activated by CNO to induce insulin release (orange circles).
Red stars show the approximate locations of the Y3.33C and A3.56G mutations which render the M3-muscarinic receptor insensitive to
acetylcholine and potently activated by clozapine-N-oxide shown above.signaling cascade for a particular process (Figure 1).
Although these pioneering chemogenetic technologies
were useful for archetypical proof-of-concept studies
[31,32], they were not widely adopted. To circumvent
problems inherent with the first-generation chemogenetic
tools (lack of inert ligands and high basal activity of recep-
tors), my lab developed DREADDs (Designer Receptors
Exclusively Activated by Designer Drugs) [21], which are
now routinely used by neuroscientists and others to modu-
late neuronal activity and cellular signaling [22].
DREADDs are also used to clarify how GPCR signaling
processes are important for mediating normal and abnormal
physiology [33,34,35,36].
DREADDs [22] are GPCRs that have been engineered to:
(a) lack appreciable responses to their endogenous ligand; (b)
have minimal basal (constitutive)activity and (c) be activated
by a pharmacologically inert ligand. Many types of
DREADDs currently exist, including those based on mus-
carinic [22], k-opioid [37] and the FFA2 fatty acid GPCRs
[38]. All of these DREADDs activate the canonical G
proteins to which they are coupled after stimulation by their
otherwise inert cognate ligand. Thus, the M2 and M4-
DREADDs (hM2Di and hM4Di, respective) activate Gi-
family proteins, M1-DREADDs, M3-DREADDs and M5-
DREADDs (hM1Dq, hM3Dq and hM5Dq respectively)activate Gq/11. The k-opioid DREADD (KORD) activates
Gi-family receptors, while the FFA2 DREADD activates Gi
and Gq family G proteins. A particularly useful DREADD
has been developed, in which the highly conserved arginine
intheconserved ‘DRY’ motifessential for receptoractivation
[3,39,40] is mutated. This particular mutation—R3.50L—
yields an M3-(R3.50L)-DREADD that is able to recruit
arrestin, but can no longer activate G protein signaling
[41]. This M3-(R3.50L)-DREADD can be used to deter-
mine the role of arrestin signaling in cellular processes.
DREADDs can be expressed via virally mediated transduc-
tion [42] or can be genetically encoded in essentially any cell
type [43,44] and activated non-invasively via drug-like small
molecules [45] to reveal the physiological consequences of
GPCR signaling in defined cells. Accordingly, DREADDs
provide a synthetic biological platform for selectively and
non-invasively modulating GPCR signaling. Here, I will
summarize emerging structural insights into the actions of
DREADDs that promise to transform and extend the use-
fulness of this chemogenetic platform.
Structural insights into muscarinic DREADD
actions
The first DREADDs were based on human muscarinic
acetylcholine receptors. These muscarinic DREADDs
(hM1Dq, hM2Di, hM3Dq, hM4Di, and hM5Dq) were
created by directed molecular evolution in yeast
[22,46] to be activated by the inert clozapine metabo-
lite clozapine-N-oxide (CNO). To date, muscarinic
DREADDs are the most widely used chemogenetic
tools in the neurosciences. Two of these — hM2Di
and hM4Di — inhibit neuronal activity [22] via Gb/
g-mediated activation of hyperpolarizing GIRK channels
and inhibition of synaptic release of neurotransmitters
[47]. The Gq-coupled DREADD (hM3Dq) is most
frequently used to enhance neuronal activity [48], via
Gq-mediated depolarization and modulation of ion chan-
nel activity [44]. When combined with Cre-responsive
viruses and genetically encoded Cre-recombinase
expressed in discrete neurons, DREADDs can be used
to remotely control neuronal activity in defined neurons
and, consequently, modulate a number of behaviors and
physiological responses [49,44].
Although widely used, these DREADDs are not without
liabilities. Thus, for instance, CNO may be metabolized
to clozapine at low levels in mice [50] and rats [51] and to a
greater extent in guinea pigs and humans [52]. As cloza-
pine is an antipsychotic drug with high affinity for a large
number of neurotransmitter receptors [53], such a con-
version may be problematic and various controls are now
recommended when using CNO [see Ref. [44] for
review]. Alternatively, CNO analogs with improved bio-
availability and without metabolic liabilities such as C21
and perlapine can also be used [45,54]. Going forward,
novel DREADD chemogenetic actuators having differ-






INACTIVE (a) (b) (c)
Structural insights into DREADD actions.
Shown are snake plots of the M2 (a) and M3 (e) [72] muscarinic receptors w
red. Panel (d) shows the active state structure of the M2 muscarinic recept
transition from inactive to active state DREADD.In discussing the structural features of DREADDs, I use
the numbering system developed by Ballesteros and
Weinstein [55]. Thus, for the muscarinic DREADDs
the conserved amino acids of interest are Y3.33 in
TM3 and A5.46 in TM5 (numbered according to Balles-
teros and Weinstein [55]). When these are mutated to
Y3.33C and A5.46G they yield muscarinic receptors
insensitive to the endogenous ligand acetylcholine and
potently activated by CNO [22] (Figure 2a and e). As
these particular mutations were arrived at via several
cycles of directed evolution and employed unusual
[non-conservative] substitutions (e.g. Y ! C and A ! G)
it was not immediately clear why these particular muta-
tions were essential for the desired chemical and biologi-
cal phenotype.
Several years after the invention of the muscarinic
DREADDs, both inactive [56] and active-state structures
of the M2 muscarinic receptor were published [57].
Figure 2 also shows an active state structure of the
wild-type M2 muscarinic receptor (2D [57]), a model
of an active state hM2Di-DREADD (Figure 2b) and a
summary of key transitions (Figure 2c). Although it is not
entirely evident from the structure why these mutations
transform CNO from a weak antagonist into an agonist,
our recent studies provide a clue. Thus, we found that a
similar A5.46G mutation of the 5-HT2B serotonin recep-
tor transforms the antagonist methysergide into a potent
agonist [58]. This is accomplished by providing bulk-
tolerance for the N-methyl group of methysergide, which
allows for the inward movement of TM5 required for
stabilizing the active state. Presumably, a similar transi-
tion in the hM2Di-DREADD (Figure 2b–d) is key forhM3Dq4MQS
2 Å
2Di
    ACTIVE (d) (e)
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ith the locations of the Y3.33C and A3.56G mutations highlighted in
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Structural features of the k-opioid DREADD.
Shown in (a) is the inactive state structure of the k-opioid receptor indicating the location of D3.32 shown in sphere representation. (b) shows a
close-up of the binding pocket of the active state k-opioid receptor highlighting the change in rotomer of D3.32 from inactive (purple) to active
(green). (c) shows a model of the k-opioid DREADD wherein the D3.32N mutated residue is pushed out of the binding pocket, freeing up energy of
desolvation for the DREADD-specific ligand salvinorin B.accommodating bulky constituents of CNO, although
direct structural studies will ultimately be essential to
determining this for certain.
Structure-inspired design of a k-opioid
DREADD
The first DREADDs were developed using an unbi-
ased, directed evolution approach and, although suc-
cessful for many applications, they suffered from the
inability to ‘multiplex’. To be able to use synthetic
biological approaches to separately activate distinct
GPCR signaling cascades sequentially or simulta-
neously in the same neurons would solve the problem
of multiplexing. With the explosion in structural infor-
mation related to GPCRs [59] we set out to use this
information to design a new DREADD. We chose as
our template the k-opioid receptor (KOR) for which a
high resolution structure was available [60] and for
which NMR-based structural information was available
for the active state [61]. We had previously discovered
that the non-nitrogenous natural product salvinorin A
was a potent and selective KOR agonist [62] and that it
did not rely on the conserved Asp3.32 found in the
binding pocket of many biogenic amine receptors [63]
for binding or activation. Indeed, Salvinorin A binding
and functional  potency were enhanced by a D3.38N
mutation while binding of the native peptide ligand
dynorphin A (1–17) was abolished [63].
Accordingly, we created a D3.38N mutant and found that
not only was Salvinorin A’s potency enhanced, but that
the relatively inert metabolite Salvinorin B (SALB) was
transformed into a potent agonist [37]. In a series of
studies, we were able to show that SALB was inert at the
tested doses in vivo but was able to afford potent andefficacious neuronal silencing in vivo in genetically
defined neurons [37]. We dubbed this the k-opioid
receptor DREADD (KORD) and note that it has been
used widely in the neurosciences to silence genetically
identified neurons [64–66]. Recent structural studies of
the active KOR have revealed a potential mechanism for
SALB’s potency at KOR [40].
In accordance with a new active state structure of KOR
[40], we found that the epoxymorphinan-derivative
MP1104 bound to KOR at some distance (2.6 Å) from
the highly conserved D3.38 (Figure 3b). The D3.38A
mutation of this residue had a modest effect on binding of
MP1104, although it abolishes binding of all known
endogenous KOR ligands [37]. The D3.38N mutation
is predicted to result in a movement of 3 Å outward from
the binding pocket due to repulsive forces with the
positively charged groups of morphinans and opioid pep-
tides. Such a movement is predicted, based on simula-
tions, to enhance SALB binding by desolvation [37]
thereby providing a molecular mechanism for SALB’s
remarkable efficacy at KORD. The D3.38N mutation
also provides repulsive energy to hinder the binding of
endogenous opioid peptides, which are known to interact
with this residue in opioid receptors for high affinity
binding [61,67] in the active state.
Future potential developments
DREADDs and other chemogenetic tools [68] along with
optogenetic technologies [69] have transformed neurosci-
ence and other disciplines. The currently available che-
mogenetic and optogenetic technologies provide many
orthogonal approaches to manipulate cellular signaling
and neuronal firing. With the current revolution occurring
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Computational approaches for structure-guided discovery of novel chemogenetic actuators.
In the top panel is shown a comparison of the D3- (purple) [73] and D4- (green) [71] dopamine receptor structures highlighting the selectivity filter
which provides a template for large-scale docking campaigns [71]. The lower panel illustrates how a similar process could be used on a mutant
receptor engineered from a template of the D4 to identify potential novel chemotypes as chemogenetic actuators.crystallography and cryo-electron microscopy, the fields
are poised to deliver a new generation of tools inspired
and designed with high resolution structural insights (see
Refs. [37,70] for examples). Combining high resolution
structures with automated docking, for instance, could
provide novel chemogenetic actuators for engineered
receptors, as has been done for native GPCRs [71]
(Figure 4).
In addition to developing novel chemogenetic actuators
and new DREADDs, it continues to be useful to engineer
GPCRs to activate designed signaling networks. Thus, for
instance, DREADDs are available for Gi [22,37], Gq[22], Gs [33] and arrestin [41] signaling, although none
are available that are selective for G12/13, gustducin,
transducin or Golf. As well, although the Gi and Gs-
selective DREADDs are currently available, they also
mobilize arrestin to at least some extent, and to have
those that do not interact with arrestin at all (as has been
done for a Gq/11-DREADD [36]) will be useful for
interrogating arrestin-dependent and independent path-
ways in cells and intact animals.
Conclusion
From the preceding examples, it should be clear that the
field of chemogenetics is maturing, and that, when
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